- Home
- FI vs VRTX Comparison
FI vs VRTX Comparison
Compare FI & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FI
- VRTX
- Stock Information
- Founded
- FI 1984
- VRTX 1989
- Country
- FI United States
- VRTX United States
- Employees
- FI N/A
- VRTX N/A
- Industry
- FI Business Services
- VRTX EDP Services
- Sector
- FI Consumer Discretionary
- VRTX Technology
- Exchange
- FI Nasdaq
- VRTX Nasdaq
- Market Cap
- FI 120.2B
- VRTX 104.8B
- IPO Year
- FI 1986
- VRTX 1991
- Fundamental
- Price
- FI $232.41
- VRTX $484.24
- Analyst Decision
- FI Strong Buy
- VRTX Buy
- Analyst Count
- FI 25
- VRTX 25
- Target Price
- FI $237.96
- VRTX $505.61
- AVG Volume (30 Days)
- FI 3.0M
- VRTX 1.5M
- Earning Date
- FI 02-05-2025
- VRTX 02-10-2025
- Dividend Yield
- FI N/A
- VRTX N/A
- EPS Growth
- FI 8.03
- VRTX N/A
- EPS
- FI 5.38
- VRTX N/A
- Revenue
- FI $20,456,000,000.00
- VRTX $11,020,100,000.00
- Revenue This Year
- FI $4.85
- VRTX $10.63
- Revenue Next Year
- FI $8.93
- VRTX $8.91
- P/E Ratio
- FI $43.19
- VRTX N/A
- Revenue Growth
- FI 7.14
- VRTX 11.66
- 52 Week Low
- FI $145.98
- VRTX $377.85
- 52 Week High
- FI $238.00
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- FI 67.03
- VRTX 65.58
- Support Level
- FI $226.35
- VRTX $451.99
- Resistance Level
- FI $238.00
- VRTX $469.55
- Average True Range (ATR)
- FI 4.23
- VRTX 11.70
- MACD
- FI 0.56
- VRTX 0.97
- Stochastic Oscillator
- FI 79.56
- VRTX 83.48
About FI Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Through the merger with First Data in 2019, Fiserv also provides payment processing services for merchants. About 10% of the company's revenue is generated internationally.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.